We would suggest designs where potential disease-modifying therapies are added as adjuncts to insulin therapy only 2–4 weeks after diabetes diagnosis in the animal models in order to replicate more closely the situation in human trials of these therapies. The gene discussed is INS; the disease is diabetes mellitus.